Kirjoita osake tai kryptovaluutta hakupalkkiin saadaksesi yhteenvedon
Simcere Pharmaceutical Group Ltd
2096Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. The company focusses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; COSELA, a trilaciclib hydrochloride for injection; Iremod, an iguratimod tablet; and XIANNUOXIN, a simnotrelvir tablets/ritonavir tablets. The company also offers promotion services for pharmaceutical products. It has a strategic regional licensing partnership with Vivoryon Therapeutics N.V. to develop and commercialize SIM0801 and other drugs in the Greater China region. In addition, the company engages in the manufacture of pharmaceutical ingredients; and property management business. Simcere Pharmaceutical Group Limited was founded in 1995 and is headquartered in Nanjing, China. Address: No. 699-18, Xuanwu Road, Nanjing, China, 210042
Analytics
WallStreetin tavoitehinta
68.51 HKDP/E-suhde
–Osinkotuotto
2.47 %Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Avainluvut 2096
Osinkoanalytiikka 2096
Osinkojen kasvu 5 vuoden aikana
–Jatkuva kasvu
1 vuosiMaksusuhde 5 vuoden keskiarvo
47 %Osinkohistoria 2096
Osakkeen arvostus 2096
Talousasiat 2096
Tuloksia | 2019 | Dynamiikka |